Fig. 2

Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS) according to the baseline neutrophil-to-eosinophil ratio (NER) (a, b), NER one month after nivolumab initiation (c, d), and relative change of NER after one month of nivolumab therapy (ΔNER) (e, f).